Moreover, HER2-AdVST (ERBB2 chimeric antigen receptor-modified adenovirus-specific cytotoxic T lymphocytes) joined to an intra-tumor injection of CAdVEC (an oncolytic adenovirus that helps the immune system) is being evaluated in an ongoing clinical trial (NCT03740256). Here, ERBB2 is linked to neoplasm.